Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-06-19T22:00:11.849Z Has data issue: false hasContentIssue false

Effect of tumour involvement on activity determination of resin Yttrium-90 in selective internal radiation therapy of metastatic liver cancer

Published online by Cambridge University Press:  29 September 2022

Jun Li*
Affiliation:
Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA
Yan Yu
Affiliation:
Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA
Rani Anne
Affiliation:
Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA
*
Author for correspondence: Jun Li, Department of Radiation Oncology, Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA 19107, USA. E-mail: Jun.Li@jefferson.edu

Abstract

Introduction:

The study was aimed to evaluate the effect of tumour involvement on resin Yttrium-90 (Y90) activity determination for metastatic liver cancer treatment.

Methods:

One hundred and two cases of resin Y90 microsphere treatment were retrospectively studied. Body surface area (BSA) method was used in the calculation of resin Y90 activity. The total activity (TA) was calculated as a summation of activities obtained from BSA-based calculation and tumour involvement (TI). TI and TA of each case were evaluated. The contributions of TI to TA were calculated with the ratio of TI/TA.

Results:

The average contribution of TI to TA was 4·1%. The contributions were < 5·8% in 75% of the cases, < 2·2% in 50% of the cases and < 1·0% in 25% of the cases.

Conclusions:

Overall the effect of tumour involvement on the activity determination was small. The activity calculation could be simplified by neglecting TI in 25% of the cases where the activity contribution from TI was less than 1%. Contouring tumour and liver structures for TI calculation could be avoided in these cases, and the efficiency of the workflow for resin Y90 procedures could be improved.

Type
Technical Note
Copyright
© The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kennedy, A, Nag, S, Salem, R et al. Recommendations for radioembolization of hepatic malignancies using Yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68 (1): 1323.CrossRefGoogle ScholarPubMed
Salem, R, Gabr, A, Riaz, A et al. Institutional decision to adopt Y-90 as primary treatment for HCC informed by a 1000-patient 15-year experience. Hepatology 2017; 68 (4): 14291440.CrossRefGoogle Scholar
SIRS-Spheres Yttrium-90 microspheres package insert. https://www.sirtex.com/us/products/sir-spheres-y-90-resin-microspheres/about-sir-spheres/approved-indication/. Accessed on 10th March 2022.Google Scholar
Bernardini, M, Smadja, C, Faraggi, M et al. Liver Selective Internal Radiation Therapy with (90)Y resin microspheres: comparison between pre-treatment activity calculation methods. Phys Med 2014; 30 (7): 752764. doi: 10.1016/j.ejmp.2014.05.004 CrossRefGoogle ScholarPubMed
Ahmadzadehfar, H, Biersack, HJ, Ezziddin, S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med 2010; 40 (2):105121. doi: 10.1053/j.semnuclmed.2009.11.001 CrossRefGoogle ScholarPubMed
Kao, YH, Tan, EH, Ng, CE, Goh, SW. Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. Ann Nucl Med 2011; 25 (7):455461. doi: 10.1007/s12149-011-0499-6 CrossRefGoogle ScholarPubMed
Kim, SP, Cohalan, C, Kopek, N, Enger, SA, A guide to 90Y radioembolization and its dosimetry, Phys Med 2019; 68: 132145.CrossRefGoogle ScholarPubMed
Tafti, BA, Padia, SA. Dosimetry of Y-90 microspheres utilizing Tc-99m SPECT and Y-90 PET. Semin Nucl Med 2019; 49 (3):211217. doi: 10.1053/j.semnuclmed.2019.01.005 CrossRefGoogle ScholarPubMed
Tong, AK, Kao, YH, Too, CW, Chin, KF, Ng, DC, Chow, PK. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol 2016; 89 (1062): 20150943. doi: 10.1259/bjr.20150943 CrossRefGoogle Scholar
Lewandowski, RJ, Salem, R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol 2006; 23 (1): 6472. doi: 10.1055/s-2006-939842 CrossRefGoogle Scholar
Metyko, J, Erwin, W, Poston, J Jr, Jimenez, S. 90Sr content in 90Y-labeled SIR-spheres and Zevalin. Health Phys 2014; 107 (5): S177S180. doi: 10.1097/HP.0000000000000171 CrossRefGoogle ScholarPubMed
Lau, WY, Kennedy, AS, Kim, YH, et al Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 2012; 82: 401407.CrossRefGoogle ScholarPubMed